| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $30.5M+57.9% | $19.3M-21.2% | $24.5M+17.9% | $20.8M+37.0% | $15.2M |
| General and administrative | $17.8M+26.4% | $14.1M+1.2% | $13.9M-1.2% | $14.1M+31.7% | $10.7M |
| Total operating expenses | $48.3M+44.6% | $33.4M-13.1% | $38.4M+10.2% | $34.8M+34.8% | $25.9M |
| Loss from operations | -$48.3M-44.6% | -$33.4M+13.1% | -$38.4M-10.6% | -$34.7M-35.0% | -$25.7M |
| Grant income | $89K | — | — | — | $1.1M |
| Interest income | $3.9M+260.5% | $1.1M-47.8% | $2.1M+70.9% | $1.2M | — |
| Interest expense | -$2.1M-1.4% | -$2.1M+19.5% | -$2.6M-51.9% | -$1.7M | — |
| Change in fair value of warrant liabilities | $8.2M+139.4% | -$20.8M-2253.4% | $966K-94.1% | $16.4M+243.3% | -$11.4M |
| Total other income (expense), net | $10.1M+146.2% | -$21.8M-4924.3% | $452K-97.2% | $15.9M+253.2% | -$10.4M |
| Net loss and comprehensive loss | -$38.2M+30.8% | -$55.2M-45.4% | -$37.9M-101.9% | -$18.8M+48.0% | -$36.1M |
| Net loss per share - basic | -$720.00+58.6% | -$1740.00-32.8% | -$1310.00-101.5% | -$650.00+66.0% | -$1910.00 |
| Net loss per share - diluted | -$720.00+58.6% | -$1740.00-32.8% | -$1310.00-101.5% | -$650.00+66.0% | -$1910.00 |
| Weighted-average common shares outstanding, basic | 52.96B+67.2% | 31.68B+9.5% | 28.94B+0.4% | 28.82B+52.7% | 18.87B |
| Weighted-average common shares outstanding, diluted | 52.96B+67.2% | 31.68B+9.5% | 28.94B+0.4% | 28.82B+52.7% | 18.87B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.